Patents Assigned to GEISTLICH PHARMA AG
-
Patent number: 9844555Abstract: New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents. Compositions and methods of using oxathiazin-like compounds and their derivatives are disclosed.Type: GrantFiled: March 29, 2017Date of Patent: December 19, 2017Assignee: Geistlich Pharma AGInventor: Rolf W. Pfirrmann
-
Patent number: 9770538Abstract: Skin regeneration or grafting is promoted utilizing a structure including a multi-layer sheet of collagen membrane material which includes a purified collagen barrier sheet material derived from natural collagen-containing tissue, the barrier sheet material including a barrier layer with an outer smooth barrier face and a fibrous face opposite the smooth barrier face. The structure further includes a matrix layer of collagen sponge material adjacent to the fibrous face. The matrix layer of collagen sponge material is resorbed by a body of a subject at a substantially faster rate than the barrier sheet material.Type: GrantFiled: January 18, 2010Date of Patent: September 26, 2017Assignee: Geistlich Pharma AGInventors: Alan S. Herford, Lothar Schloesser, Peter Geistlich
-
Publication number: 20170196876Abstract: New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents. Compositions and methods of using oxathiazin-like compounds and their derivatives are disclosed.Type: ApplicationFiled: March 29, 2017Publication date: July 13, 2017Applicant: Geistlich Pharma AGInventor: Rolf W. PFIRRMANN
-
Patent number: 9655997Abstract: A resilient resorbable chemically crosslinked collagen sponge for promoting soft tissue volume augmentation in the oral region, comprising 60-96% (w/w) collagen and 4-40% (w/w) elastin, which shows by mercury intrusion porosimetry interconnected pores with a median pore diameter between 50 and 90 ?m and at least 80% porosity with a pore diameter more than 10 ?m, an onset temperature of 45 to 57° C. and a density in dry state from 50 to 65 mg/cm3. A process for preparing a resilient resorbable chemically crosslinked collagen sponge. A method of using a resilient resorbable chemically crosslinked collagen sponge as an implant in the oral cavity for soft tissue volume augmentation.Type: GrantFiled: December 15, 2015Date of Patent: May 23, 2017Assignee: Geistlich Pharma AGInventors: Cornel Imhof, Lothar Schloesser, Niklaus Stiefel, Martin Wuest
-
Patent number: 9624187Abstract: New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents. Compositions and methods of using oxathiazin-like compounds and their derivatives are disclosed.Type: GrantFiled: December 3, 2015Date of Patent: April 18, 2017Assignee: Geistlich Pharma AGInventor: Rolf W. Pfirrmann
-
Publication number: 20160166737Abstract: A resilient resorbable chemically crosslinked collagen sponge for promoting soft tissue volume augmentation in the oral region, comprising 60-96% (w/w) collagen and 4-40% (w/w) elastin, which shows by mercury intrusion porosimetry interconnected pores with a median pore diameter between 50 and 90 ?m and at least 80% porosity with a pore diameter more than 10 ?m, an onset temperature of 45 to 57° C. and a density in dry state from 50 to 65 mg/cm3. A process for preparing a resilient resorbable chemically crosslinked collagen sponge. A method of using a resilient resorbable chemically crosslinked collagen sponge as an implant in the oral cavity for soft tissue volume augmentation.Type: ApplicationFiled: December 15, 2015Publication date: June 16, 2016Applicant: Geistlich Pharma AGInventors: Cornel IMHOF, Lothar SCHLOESSER, Niklaus STIEFEL, Martin WUEST
-
Publication number: 20160159759Abstract: New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents. Compositions and methods of using oxathiazin-like compounds and their derivatives are disclosed.Type: ApplicationFiled: December 3, 2015Publication date: June 9, 2016Applicant: Geistlich Pharma AGInventor: Rolf W. PFIRRMANN
-
Publication number: 20160144071Abstract: The invention relates to: a biomimetic collagen-hydroxyapatite composite material comprising an at least partially fibrous collagen scaffold including mature native collagen fibers possessing triple helicity as shown by Circular Dichroism Spectroscopy, wherein those mature native collagen fibers are at least partially covered with epitactically grown crystals of nanocrystalline hydroxyapatite, whereby the epitactically grown nanocrystals have the same morphology as human bone mineral and the same size as human bone mineral, i.e.Type: ApplicationFiled: July 18, 2014Publication date: May 26, 2016Applicant: GEISTLICH PHARMA AGInventor: Michael BUFLER
-
Patent number: 9241943Abstract: New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents.Type: GrantFiled: June 17, 2013Date of Patent: January 26, 2016Assignee: Geistlich Pharma AGInventor: Rolf W. Pfirrmann
-
Publication number: 20150182556Abstract: The invention provides: —A hydrophilic dehydrated partially purified bone replacement material of natural origin, wherein substantially all non-collagenous organic material is removed while inorganic, porous osseous structure and collagenous structure of natural bone are substantially preserved, characterized in that the bone replacement material contains 0.05 to 1.5 w/w % of at least one of a saccharide or a sugar alcohol, and 0.7 to 5.6 w/w % of a phosphate group selected from the group consisting of phosphate HPO42? and H2PO4?, this phosphate group being part of a physiologically acceptable salt and—a process for preparing a hydrophilic dehydrated partially purified bone replacement material.Type: ApplicationFiled: July 29, 2013Publication date: July 2, 2015Applicant: GEISTLICH PHARMA AGInventors: Cornel Imhof, Lothar Schlösser, Birgit Schäfer, Michael Bufler
-
Publication number: 20150182534Abstract: New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents.Type: ApplicationFiled: June 17, 2013Publication date: July 2, 2015Applicant: GEISTLICH PHARMA AGInventor: Rolf W. Pfirrmann
-
Patent number: 9066995Abstract: The invention relates to: —a porous biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material comprising a sintered CAP core and at least one uniform and closed epitactically grown layer of nanocrystalline HAP deposited on top of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, i.e.Type: GrantFiled: December 21, 2011Date of Patent: June 30, 2015Assignee: GEISTLICH PHARMA AGInventor: Michael Alexander Bufler
-
Patent number: 9028866Abstract: It now has been found that oral administration of pharmaceutical agents, including N-methylol transfer agents such as Taurolidine may be used to provide efficacious blood plasma concentration of the agents for treatment of diseases by providing release of the active agent into the duodenum or jejunum of a patient and/or at a pH of about 5.4 to about 6.5. Embodiments of the invention therefore provide oral dosage forms, compositions and methods for administration of pharmaceutical agents to the duodenum or jejunum of a patient, and/or which release at a pH of about 5.4 to about 6.5.Type: GrantFiled: June 1, 2011Date of Patent: May 12, 2015Assignee: Geistlich Pharma AGInventors: Rolf W. Pfirrmann, Peter Geistlich
-
Patent number: 8992946Abstract: Tissue regeneration or grafting is promoted utilizing a structure including a multi-layer sheet of collagen membrane material which includes a purified collagen barrier sheet material derived from natural collagen-containing tissue, the barrier sheet material including a barrier layer with an outer smooth barrier face and a fibrous face opposite the smooth barrier face. The structure further includes a matrix layer of collagen sponge material adjacent to the fibrous face. The matrix layer of collagen sponge material is resorbed by a body of a subject at a substantially faster rate than the barrier sheet material.Type: GrantFiled: January 18, 2010Date of Patent: March 31, 2015Assignee: Geistlich Pharma AGInventors: Peter Geistlich, Lothar Schloesser
-
Patent number: 8852617Abstract: A dental care preparation in a form of a toothpaste or tooth gel dentifrice includes an antimicrobial amount of at least one antimicrobial N-methylol transfer agent, and at least one of a fluoride compound or a source of fluoride ions.Type: GrantFiled: September 26, 2011Date of Patent: October 7, 2014Assignee: Geistlich Pharma AGInventors: Rolf W. Pfirrmann, Peter Geistlich
-
Patent number: 8852580Abstract: An implant for repair of a cartilaginous defect in a subject includes a collagen matrix charged with synovial cells. A method preparing an implant for repair of a cartilaginous defect in a subject includes obtaining a fluid containing synovial cells and charging the synovial cells to the matrix. A device for preparing a cell-charged implant includes a first chamber and a second chamber, the first and second chambers being separated by a membrane and a perforated filter. The membrane is adapted to collect cells from a cell-containing fluid introduced into the first chamber and the perforated filter is adapted to permit passage or diffusion of the fluid through the second chamber. A method for preparing a cell-charged implant utilizes the device.Type: GrantFiled: September 13, 2012Date of Patent: October 7, 2014Assignee: Geistlich Pharma AGInventors: Birgit Schaefer, Lothar Schloesser
-
Patent number: 8734524Abstract: The invention relates to: —a biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material comprising a sintered CAP core and at least one uniform and closed epitactically grown layer of nanocrystalline HAP deposited on top of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, i.e. a length of 30 to 46 nm and a width of 14 to 22 nm, —a process of preparing the above CAP/HAP bone substitute material comprising the steps of a) preparing a sintered CAP core material, b) immersing the sintered CAP core material in an aqueous solution at a temperature between 10° C. and 50° C.Type: GrantFiled: June 15, 2010Date of Patent: May 27, 2014Assignee: Geistlich Pharma AGInventor: Michael Alexander Bufler
-
Publication number: 20130345825Abstract: The invention relates to: —a porous biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material comprising a sintered CAP core and at least one uniform and closed epitactically grown layer of nanocrystalline HAP deposited on top of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, i.e.Type: ApplicationFiled: December 21, 2011Publication date: December 26, 2013Applicant: GEISTLICH PHARMA AGInventor: Michael Alexander Bufler
-
Publication number: 20130189199Abstract: A dental care preparation in a form of a toothpaste or tooth gel dentifrice includes an antimicrobial amount of at least one antimicrobial N-methylol transfer agent, and at least one of a fluoride compound or a source of fluoride ions.Type: ApplicationFiled: September 26, 2011Publication date: July 25, 2013Applicant: GEISTLICH PHARMA AGInventors: Rolf W. Pfirrmann, Peter Geistlich
-
Patent number: D721803Type: GrantFiled: September 14, 2012Date of Patent: January 27, 2015Assignee: Geistlich Pharma AGInventor: Werner F. Dubach